Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 36Completed 13Active not recruiting 13Terminated 7Not yet recruiting 5Unknown 4Withdrawn 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Glioblastoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Select Advanced Solid Tumors 1Sarcoma 1Recurrence 1Prostate Adenocarcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Glioma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1

Interventions

Sorafenib 13Radiosurgery 9spartalizumab 7lenvatinib 7Oxaliplatin 6Gemcitabine 5Fluorouracil 5Radiotherapy 4Cisplatin 4Bevacizumab 4atezolizumab 3Leucovorin 3Folfox protocol 3Doxorubicin 3gadolinium ethoxybenzyl DTPA 2fludarabine 2cabozantinib 2Nivolumab 2Mitomycin 2Electroporation 2Cyclophosphamide 2Chemoembolization, Therapeutic 2tremelimumab 1toripalimab 1tocilizumab 1tislelizumab 1temsirolimus 1tazemetostat 1sitravatinib 1pirarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Hepatocellular × atezolizumab × Clear all
NCT06006286 2024-08-26

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT05109052 2023-07-13

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

University of Rochester

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05327738 2022-12-14

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

OHSU Knight Cancer Institute

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡